Gene Expression Analyses of HER-2/neu and ESR1 in Patients with Breast Cancer
AUTOR(ES)
Nadergoli, Omid Kheyri, Feizi, Mohammad Ali Hosseinpour, Kafil, Hossein Samadi, Pouladi, Nasser, Hosseinzadeh, Ali, Rostamizadeh, Leila, Montazeri, Vahid, Fakhrjou, Ashraf, Sakhinia, Ebrahim, Seifi, Morteza
FONTE
Braz. arch. biol. technol.
DATA DE PUBLICAÇÃO
05/10/2017
RESUMO
ABSTRACT Background: Her-2 and ESR1 genes, that interact in the cell signaling pathway, are the most important molecular markers of breast cancer, which have been amplified or overexpressed in 30% and 70%, respectively. This study was performed to evaluate the gene expression levels of Her-2 and ESR1 genes in tumor cells and its adjacent normal tissue of breast cancer patients and compared them whit clinical-pathological features. Methods: In total, 80 tissue specimens from 40 patients, with an average age of 48.47 years, were examined by Real-time PCR technique, and ultimately evaluated the expression level of Her-2 and ESR1genes. The data were analyzed by REST 2009 V2.0.13 statistical software. Results: HER2 and ESR1 overexpression was identified in 19 (48%) and 12 (30%) of 40 patients respectively, which was higher and lower than that recorded in international statistics, respectively. ESR1 overexpression was associated with Stage 3A and lymph node involvement 2 (N2) (P = 0.04 and P = 0.047, respectively). No significant correlation was observed between the expression of HER2 and ESR1 and other clinical-pathological features, however, the relative differences were identified in the expression levels of genes between main group and groups that were classified according to the clinical-pathological features and age. Conclusions: Overexpression of Her-2 and ESR1 genes in the patients of our study are higher and lower than international statistics, respectively, indicating the differences in genetic, environmental and ethnic factors that involved in the developing of breast cancer.
Documentos Relacionados
- Gene Expression Analyses of HER-2/neu and ESR1 in Patients with Breast Cancer
- Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
- Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells.
- Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
- Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.